I’m sorry to have to put it this bluntly because I value your contributions a great deal but your take here is so sloppy I’m a bit shocked.
https://www.medpagetoday.com/meetingcoverage/ctad/112713#:~:text=High-dose%20supplements%20of%20docosahexaenoic,has%20been%20inconsistent%2C%20he%20noted.
High-dose supplements of docosahexaenoic acid (DHA), an omega-3 fatty acid, penetrated the brain in both APOE4 carriers and non-carriers before dementia onset, the placebo-controlled PreventE4 trial showed.
The treatment did not influence hippocampal volume, said Hussein Yassine, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles. However, increases in brain DHA in both the treatment and placebo arms were associated with better cognitive measures in APOE4 carriers, Yassine reported at the Clinical Trials on Alzheimer’s Diseaseopens in a new tab or window annual meeting in Madrid.
“Omega-3s are good for the APOE4 brain when started before dementia symptoms,” Yassine told MedPage Today. “This is different in dementia, when APOE4 carriers have a lower increase in brain DHA after supplementation than non-carriers,” he pointed out.
“What’s novel about these findings is that the benefit was greater for those with Alzheimer’s genetic risk,” he added.
Lower blood omega-3 levels have been correlated with worse cognitive function in several observational cohorts, particularly among APOE4carriers, but the effect of omega-3 supplementation on cognitive outcomes in clinical trials has been inconsistent, he noted.
“In general, very few studies have examined brain DHA delivery as a metric for treatment efficacy,” Yassine said.
DHA is mostly obtained from fatty fish consumption. It’s the predominant omega-3 in the brain by weight and comprises up to 40% of fatty acids in gray matter.
Earlier studies showed that the brains of young (age 35) cognitively normal APOE4 carriers were more dependent on circulating DHAopens in a new tab or window than non-APOE4 brains.
“This means that the APOE4 brain is taking more DHA from plasma into the brain for its normal biological processes,” Yassine said. “It consumes more DHA, like a specific engine that requires a specific oil to function.”
Since plasma DHA levels are largely determined by dietary intake, this finding implies vulnerability of APOE4 carriers to a low DHA diet, he noted.
PreventE4opens in a new tab or window was a double-blind, single-center trial of cognitively unimpaired individuals with at least one vascular dementia risk factor and limited seafood consumption (DHA intake less than 200 mg/day). People who used omega-3 supplements in the last 3 months were excluded. By design, half the study population had at least one APOE4allele.
It shows the opposite of what you claimed! Even if there was no difference to cognition among the study’s arms, it wouldn’t have proven anything as 6 months (or was it 2 years?) isn’t enough time to create a delta in outcomes. What’s important here is that it proves dietary supplementation of DHA DOES make it up the apoE4 carrier’s brain. This is news to me and maybe I’m wasting money and taking extra pills I don’t have to by opting for the phospholipid form. Doesn’t affect hippocampus volume but so what? It actually does seem to make a difference to cognition.
Anyway, I don’t mean to be rude. You’re as good a contributor as they get. Just surprising to me how you could interpret something for its obvious opposite.